EX-10.2



 Exhibit 10.2 

EMPLOYMENT AGREEMENT 

This EMPLOYMENT AGREEMENT (the “Agreement”) is made as of January 5, 2016 by and between Ocular Therapeutix, Inc., a Delaware
corporation (the “Company”), and Jon Talamo, M.D. (“Executive”). In consideration of the mutual covenants contained in this Agreement, the Company and Executive agree as follows: 

1. Employment. The Company agrees to employ Executive and Executive agrees to be employed by the Company on the terms and conditions
set forth in this Agreement. 
 (a) Capacity. Executive shall serve the Company as Chief Medical Officer, working an 80% (on average
four (4) day per week) schedule (the “Reduced Schedule”) and reporting to Amar Sawhney, President, Chief Executive Officer and Chairman (the “CEO”). During the Term (as defined below) of Executive’s employment with the
Company, Executive shall, subject to the direction of the CEO, have the responsibilities, duties and authority commensurate with the position of Chief Medical Officer (including, without limitation, those duties and responsibilities set forth on
Exhibit A hereto) and shall perform such other duties as may from time to time be assigned to him by the Company. The Company may change Executive’s position, duties, and work location as it deems necessary. 

 

	 	1.	 Devotion of Duties; Representations. During the Term of Executive’s employment with the Company,
Executive shall devote (during his Reduced Schedule or, if he ceases to work a Reduced Schedule, during his full-time employment with the Company) his best efforts and full business time and energies to the business and affairs of the Company, and
shall endeavor to perform the duties and services contemplated hereunder to the reasonable satisfaction of the Company. Except as set forth below, during the Term of Executive’s employment with the Company, Executive shall not engage in any
other business activities without the prior written approval of the Company (by action of the Board), including undertaking any other employment from any person or entity or serving as a director of any other company; provided, however, that
(i) the Company will entertain requests as to such other employment or directorships in good faith and (ii) Executive will be eligible to participate in any policy relating to outside activities that is applicable to the senior executives
of the Company and approved by the Board after the date hereof, and provided further that in no event may any business activity be undertaken if it would (x) be in violation of any provision of this Agreement or other agreement between
Executive and the Company, (y) interfere with the performance of Executive’s duties for the Company, or (z) present a conflict of interest with the Company’s business interests. The Company acknowledges that, while working the
Reduced Schedule, (a) Executive may continue to practice medicine and may enter into business arrangements that allow him to do so, and (b) Executive may continue to serve as a consultant to Abbott Medical Optics, Aura Biosciences, Carl
Zeiss Meditec, CXL Ophthalmics, Intersystems, Santen and Shire plc, unless the Company determines in its sole discretion that his continued services pursuant to (a) and/or (b) above (i) pose a conflict of interest with respect to his
duties on behalf of the Company, (ii) would result in a violation of any provision of this Agreement or any other agreement between Executive and the Company, and/or (iii) would prevent Executive from fulfilling his duties hereunder to the
Company, in which event continued services pursuant to (a) and/or (b) above would no longer be permitted. In the event that Executive ceases to 









 
work the Reduced Schedule and becomes a full time employee of the Company, then the Company shall have the right, in its sole discretion, to review all of Executive’s then-existing other
business activities to determine whether the Company will continue to consent to Executive’s participation in such activities. 
 2.
Term of Employment. 
 (a) Executive’s employment hereunder shall begin on January 8, 2016 (the “Effective
Date”). Executive’s employment hereunder shall be terminated upon the first to occur of the following: 
 (i)
Immediately upon Executive’s death; 
 (ii) By the Company, by written notice to Executive effective as of the
date of such notice (or on such other date as specified in such notice): 
 (A) Following the Disability of Executive.
“Disability” means that Executive (i) is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last
for a continuous period of not less than twelve (12) months or (ii) is, by reason of any medically determinable physical or mental impairment which can be expected to last for a continuous period of not less than twelve (12) months,
receiving income replacement benefits for a period of not less than three (3) months under an accident and health plan covering employees of the Company. Such incapacity shall be determined by a physician chosen by the Company and reasonably
satisfactory to Executive (or Executive’s legal representative) upon examination requested by the Company (to which Executive hereby agrees to submit). Notwithstanding the foregoing, such Disability must result in Executive becoming
“Disabled” within the meaning of Section 409A(a)(2)(C) of the Internal Revenue Code of 1986, as amended (the “Code”) and the guidance issued thereunder. (In this Agreement we refer to Section 409A of the Code and any
guidance issued thereunder as “Section 409A.”) 
 (B) For Cause (as defined below); or 

(C) Subject to Section 4 hereof, without Cause; 

(iii) By Executive: 

(A) At any time by written notice to the Company, effective thirty (30) days after the date of such notice; or 

(B) By written notice to the Company for Good Reason (as defined below), effective on the date specified in such notice. 

The term of Executive’s employment by the Company under this Agreement is referred to herein as the “Term.” 

  
 - 2 - 








 (b) Definition of “Cause”. For purposes of this Agreement, “Cause”
shall, pursuant to the reasonable good faith determination by the Company as documented in writing, include: (i) the willful and continued failure by Executive to substantially perform Executive’s material duties or responsibilities under
this Agreement (other than such a failure as a result of Disability); (ii) any action or omission by Executive involving willful misconduct or gross negligence with regard to the Company, which has a detrimental effect on the Company;
(iii) Executive’s conviction of a felony, either in connection with the performance of Executive’s obligations to the Company or which otherwise shall adversely affect Executive’s ability to perform such obligations or shall
materially adversely affect the business activities, reputation, goodwill or image of the Company; (iv) the material breach of a fiduciary duty to the Company; or (v) the material breach by Executive of any of the provisions of this
Agreement, provided that any breach of Executive’s obligations with respect to Sections 5 or 6 of this Agreement, subject to the cure provision in the next sentence, shall be deemed “material.” In respect of the events described in
clauses (i) and (v) above, the Company shall give Executive notice of the failure of performance or breach, reasonable as to time, place and manner in the circumstances, and a 30-day opportunity to cure, provided that such failure of
performance or breach is reasonably amenable to cure as determined by the Company in its sole discretion. 
 (c) Definition of “Good
Reason”. For purposes of this Agreement, a “Good Reason” shall mean any of the following, unless (i) the basis for such Good Reason is cured within a reasonable period of time (determined in the light of the cure appropriate
to the basis of such Good Reason, but in no event less than thirty (30) nor more than ninety (90) days) after the Company receives written notice (which must be received from Executive within ninety (90) days of the initial existence
of the condition giving rise to such Good Reason) specifying the basis for such Good Reason or (ii) Executive has consented to the condition that would otherwise be a basis for Good Reason: 

(i) A change in the principal location at which Executive provides services to the Company to a location more than fifty
(50) miles from such principal location (which change, the Company has reasonably determined as of the date hereof, would constitute a material change in the geographic location at which Executive provides services to the Company), provided
that such a relocation shall not be deemed to occur under circumstances where Executive’s responsibilities require him to work at a location other than the corporate headquarters for a reasonable period of time; 

(ii) A material adverse change by the Company in Executive’s duties, authority or responsibilities which causes
Executive’s position with the Company to become of materially less responsibility or authority than Executive’s position immediately following the Effective Date where such change is not remedied within ten (10) business days after
written notice thereof by Executive; 
 (iii) A material reduction in Executive’s base salary; 

(iv) A material breach of this Agreement by the Company which has not been cured within thirty (30) days after written
notice thereof by Executive; or 
 (v) Failure to obtain the assumption (assignment) of this Agreement by any successor to
the Company. 

  
 - 3 - 








 (d) Definition of “Corporate Change”. For purposes of this Agreement,
“Corporate Change” shall mean any circumstance in which (i) the Company is not the surviving entity in any merger, consolidation or other reorganization (or survives only as a subsidiary or affiliate of an entity other than a
previously wholly-owned subsidiary of the Company); (ii) the Company sells, leases or exchanges all or substantially all of its assets to any other person or entity (other than a wholly-owned subsidiary of the Company); (iii) any person or
entity, including a “group” as contemplated by Section 13(d)(3) of the Securities Exchange Act of 1934 (excluding, for this purpose, the Company or any subsidiary, or any employee benefit plan of the Company or any subsidiary, or any
“group” in which all or substantially all of its members or its members’ affiliates are individuals or entities who are or were beneficial owners of the Company’s outstanding shares prior to the initial public offering of the
Company’s common stock, if any, of the Company’s stock), acquires or gains ownership or control (including, without limitations, powers to vote) of more than 50% of the outstanding shares of the Company’s voting stock (based upon
voting power); or (v) as a result of or in connection with a contested election of directors, the persons who were directors of the Company before such election shall cease to constitute a majority of the Board of Directors of the Company.
Notwithstanding the foregoing, a “Corporate Change” shall not occur as a result of a merger, consolidation, reorganization or restructuring after which either (1) a majority of the Board of Directors of the controlling entity consists
of persons who were directors of the Company prior to the merger, consolidation, reorganization or restructuring or (2) all or substantially all of the individuals or entities who were the beneficial owners of the Company’s outstanding
shares immediately prior to such merger, consolidation, reorganization or restructuring beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding
securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in substantially the same proportions as their ownership of the Company’s outstanding shares immediately prior to the
merger, consolidation, reorganization or restructuring. Notwithstanding the foregoing, for any payments or benefits hereunder (including pursuant to Section 4(b)(iii) hereof) or pursuant to any other agreement between the Company and Executive,
in either case that are subject to Section 409A, the Corporate Change must constitute a “change in control event” within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i). 

3. Compensation. 
 (a)
Base Salary. Except as provided below, Executive’s minimum base salary during the Term shall be at the rate of $300,000 per year based on Executive’s Reduced Schedule. If Executive ceases working the Reduced Schedule and converts to
full time employment, Executive’s base salary shall be increased by 25%. Executive’s base salary shall be payable in substantially equal installments in accordance with the Company’s payroll practices as in effect from time to time,
less any amounts required to be withheld under applicable law. The base salary will be subject to adjustment from time to time in the sole discretion of the Company; provided that, the Company covenants that (A) during the first twelve months
of Executive’s employment, it shall not reduce Executive’s base salary and (B) following such twelve month period, it shall not reduce the base salary below the base salary then in effect immediately prior to the reduction unless
(i) Executive consents to such reduction, or (ii) the reduction is in connection with a general reduction of not more than 20% in compensation of senior executives of the Company generally that occurs prior to the effective date of any
Corporate Change. 

  
 - 4 - 








 (b) Bonus. In addition to the base salary, the Company may pay Executive an annual bonus
(the “Bonus”) as determined by the Board, solely in its discretion (it being understood that Executive’s target annual bonus shall be thirty five percent (35%) of Executive’s base salary in effect for such year, but may be
higher or lower in any year in the Board’s discretion). The Board’s decision to issue a Bonus to Executive in any particular year shall have no effect on the absolute discretion of the Board to grant or not to grant a Bonus in subsequent
years. Any Bonus for a particular year shall be paid or provided to Executive in a lump sum no later than March 15th of the calendar year following the calendar year in which the Bonus was
earned. 
 (c) Stock Option Program. Executive will be eligible to participate in the Company’s stock option program.
Subject to approval by the Company’s Board of Directors, the Company will grant to Executive an option to purchase 72,000 shares of the Company’s Common Stock (the “New Hire Option”) and if, within the first year of
Executive’s employment, Executive ceases working the Reduced Schedule and converts to a full time employee, the Company will grant to Executive an option to purchase an additional 18,000 shares of the Company’s Common Stock (the
“Additional New Hire Option” and, together with the New Hire Option, the “Options”). Both Options are subject to adjustment for stock splits, combinations, or other recapitalizations. The stock option exercise price shall be
equal to the closing price as quoted on the NASDAQ stock exchange on the date of approval of the New Hire Option and, if applicable, the date of approval of the Additional New Hire Option, in either case by the Board of Directors. Each Option shall
be issued pursuant to the Company’s 2014 Equity Incentive Plan, as amended, and will be subject to all of the terms and conditions set forth in such plan and the Stock Option Agreement covering the Option. 

(d) Vacation. While working the Reduced Schedule, Executive shall be entitled to take sixteen (16) days of paid vacation during
each year of the Term to be taken at such time or times as shall be mutually convenient and consistent with his duties and obligations to the Company. If Executive ceases to work a Reduced Schedule and converts to full time employment status,
Executive shall be entitled to take twenty (20) days of paid vacation on the same terms stated above. The number of vacation days for which Executive is eligible shall accrue at the rate of 1.33 days per month that he works the Reduced Schedule
(or 1.66 days per month if he ceases to work the Reduced Schedule and converts to a full time employee). Vacation is at all times subject to the Company’s Time-Off Policy, which the Company may change periodically in its sole discretion. 

(e) Fringe Benefits. Executive shall be entitled to participate in any employee benefit plans that the Company makes available to its
executives (including, without limitation, group life, disability, medical, dental and other insurance, retirement, pension, profit-sharing and similar plans) (collectively, the “Fringe Benefits”), provided that the Fringe Benefits shall
not include any stock option or similar plans relating to the grant of equity securities of the Company. These benefits may be modified or changed from time to time at the sole discretion of the Company. Where a particular benefit is subject to a
formal plan (for example, medical or life insurance), eligibility to participate in and receive any particular benefit is governed solely by the applicable plan document, and eligibility to participate in such plan(s) may be dependent upon, among
other things, a physical examination. 
 (f) Reimbursement of Expenses. Executive shall be entitled to reimbursement for all ordinary
and reasonable out-of-pocket business expenses that are reasonably incurred by him in furtherance of the Company’s business in accordance with reasonable policies adopted from time to time by the Company for senior executives, subject to
Section 4(d)(v). 

  
 - 5 - 








 (g) Withholdings. All compensation payable to Executive shall be subject to applicable
taxes and withholdings. 
 4. Severance Compensation. 

(a) In the event of any termination of Executive’s employment for any reason, the Company shall pay Executive (or Executive’s
estate) such portions of Executive’s base salary as have accrued prior to such termination and have not yet been paid, together with (i) amounts for accrued unused vacation days (as provided above), (ii) any amounts for expense
reimbursement which have been properly incurred or the Company has become obligated to pay prior to termination and have not been paid as of the date of such termination and (iii) the amount of any Bonus previously granted to Executive by the
Board but not yet paid, which amount shall not include any pro rata portion of any Bonus which would have been earned if such termination had not occurred (the “Accrued Obligations”). Such Accrued Obligations shall be paid as soon as
possible after termination. 
 (b) In the event that Executive’s employment hereunder is terminated (i) by Executive for a Good
Reason or (ii) by the Company without Cause, the Company shall pay to Executive the Accrued Obligations. In addition, the Company shall pay to Executive the severance benefits set forth below for twelve (12) months, or for eighteen
(18) months if such termination occurs during the twelve (12) month period following a Corporate Change (the “Protected Period”), following Executive’s termination of employment (as applicable, the “Severance
Period”). The receipt of any severance benefits provided in this Section shall be dependent upon Executive’s execution and nonrevocation of a standard separation agreement and general release of claims, substantially in the form attached
hereto as Exhibit B (the “Release”). The distribution of severance benefits in this Section 4 is subject to Section 4(d). 

(i) The Company shall continue to pay Executive his base salary for the Severance Period in accordance with the Company’s
payroll practice, beginning on the Company’s first regular payroll date that occurs on or after the 30th day following Executive’s termination of employment, provided that the Release
has been executed and any applicable revocation period has expired as of such date. Notwithstanding the foregoing, if Executive’s termination of employment occurs during the Protected Period, the Company shall pay Executive his base salary for
the Severance Period in a lump sum 30 days following Executive’s termination of employment, provided that the Release has been executed and any applicable revocation period has expired as of such date. 

(ii) Only if Executive’s employment is terminated (A) by Executive for a Good Reason or (B) by the Company
without Cause, in each case during the Protected Period, the Company shall pay Executive an amount equal to one and one-half times his target annual bonus, described in Section 3(b) hereof, for the year in which the termination of employment
occurs, which total amount shall be payable in a lump sum 30 days following Executive’s termination of employment, provided that the Release has been executed and any applicable revocation period has expired as of such date. 

  
 - 6 - 








 (iii) Only if Executive’s employment is terminated (A) by Executive for
a Good Reason or (B) by the Company without Cause, in each case during the Protected Period, one hundred percent (100%) of Executive’s outstanding unvested equity awards granted under the Company’s equity and long-term incentive
plan(s) prior to his termination shall vest immediately. 
 (iv) The Company shall continue to provide Executive and his
then-enrolled eligible dependents with group health insurance and shall continue to pay the amount of the premium as in effect on the date of such termination for the Severance Period commencing on the effective date of such termination, subject to
applicable law and the terms of the respective policies; provided that the Company’s obligation to provide the benefits contemplated herein shall terminate upon Executive’s becoming eligible for coverage under the medical benefits program
of a subsequent employer. The foregoing shall not be construed to extend any period of continuation coverage (e.g., COBRA) required by Federal law. 

(c) In the event that Executive’s employment hereunder is terminated (i) by Executive for other than a Good Reason, or (ii) by
the Company for Cause, or (iii) as a result of Executive’s death or Disability, then the Company will pay to Executive the Accrued Obligations. The Company shall have no obligation to pay Executive (or Executive’s estate) any other
compensation following such termination except as provided in Section 4(a). 
 (d) Compliance with Section 409A. Subject to
the provisions in this Section 4(d), any severance payments or benefits under this Agreement shall begin only upon the date of Executive’s “separation from service” (determined as set forth below) which occurs on or after the
date of termination of Executive’s employment. The following rules shall apply with respect to the distribution of the severance payments and benefits, if any, to be provided to Executive under this Agreement: 

(i) It is intended that each installment of the severance payments and benefits provided under this Agreement shall be treated
as a separate “payment” for purposes of Section 409A. Neither the Company nor Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required
by Section 409A. 
 (ii) If, as of the date of Executive’s “separation from service” from the Company,
Executive is not a “specified employee” (within the meaning of Section 409A), then each installment of the severance payments and benefits shall be made on the dates and terms set forth in this Agreement. 

(iii) If, as of the date of Executive’s “separation from service” from the Company, Executive is a
“specified employee” (within the meaning of Section 409A), then: 
 (A) Each installment of the severance
payments and benefits due under this Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the short-term deferral period (as defined
under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A and such payments and benefits shall be paid or
provided on the dates and terms set forth in this Agreement; and 

  
 - 7 - 








 (B) Each installment of the severance payments and benefits due this Agreement
that is not described in Section 4(d)(iii)(A) above and that would, absent this subsection (B), be paid within the six-month period following Executive’s “separation from service” from the Company shall not be paid until the date
that is six months and one day after such separation from service (or, if earlier, Executive’s death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date
that is six months and one day following Executive’s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this
sentence shall not apply to any installment of severance payments and benefits if and to the maximum extent that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the
application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of Executive’s second taxable year following the taxable year in which the separation from service occurs. 

(iv) The determination of whether and when Executive’s separation from service from the Company has occurred shall be
made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h). Solely for purposes of this Section 4(d)(iv), “Company” shall include
all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Code. 

(v) All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the
requirements of Sections 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during Executive’s
lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year,
(iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or
exchange for any other benefit. 
 (vi) Notwithstanding anything herein to the contrary, the Company shall have no liability
to Executive or to any other person if the payments and benefits provided hereunder that are intended to be exempt from or compliant with Section 409A are not so exempt or compliant. 

  
 - 8 - 








 (e) Modified Section 280G Cutback. 

(i) Notwithstanding any other provision of this Agreement, except as set forth in Section 4(e)(ii), in the event that the
Company undergoes a “Change in Ownership or Control” (as defined below), the Company shall not be obligated to provide to Executive a portion of any “Contingent Compensation Payments” (as defined below) that Executive would
otherwise be entitled to receive to the extent necessary to eliminate any “excess parachute payments” (as defined in Section 280G(b)(1) of the Code) for Executive. For purposes of this Section 4(e), the Contingent Compensation
Payments so eliminated shall be referred to as the “Eliminated Payments” and the aggregate amount (determined in accordance with Treasury Regulation Section 1.280G-1, Q/A-30 or any successor
provision) of the Contingent Compensation Payments so eliminated shall be referred to as the “Eliminated Amount.” 

(ii) Notwithstanding the provisions of Section 4(e)(i), no such reduction in Contingent Compensation Payments shall be
made if (1) the Eliminated Amount (computed without regard to this sentence) exceeds (2) 100% of the aggregate present value (determined in accordance with Treasury Regulation Section 1.280G-1, Q/A-31 and Q/A-32 or any successor
provisions) of the amount of any additional taxes that would be incurred by Executive if the Eliminated Payments (determined without regard to this sentence) were paid to him (including federal and state income taxes on the Eliminated Payments, the
excise tax imposed by Section 4999 of the Code payable with respect to all of the Contingent Compensation Payments in excess of Executive’s “base amount” (as defined in Section 280G(b)(3) of the Code), and any withholding
taxes). The override of such reduction in Contingent Compensation Payments pursuant to this Section 4(e)(ii) shall be referred to as a “Section 4(e)(ii) Override.” For purpose of this paragraph, if any federal or state income
taxes would be attributable to the receipt of any Eliminated Payment, the amount of such taxes shall be computed by multiplying the amount of the Eliminated Payment by the maximum combined federal and state income tax rate provided by law. 

(iii) For purposes of this Section 4(e) the following terms shall have the following respective meanings: 

(1) “Change in Ownership or Control” shall mean a change in the ownership or effective control of the Company or in
the ownership of a substantial portion of the assets of the Company determined in accordance with Section 280G(b)(2) of the Code. 

(2) “Contingent Compensation Payment” shall mean any payment (or benefit) in the nature of compensation that is made
or made available (under this Agreement or otherwise) to a “disqualified individual” (as defined in Section 280G(c) of the Code) and that is contingent (within the meaning of Section 280G(b)(2)(A)(i) of the Code) on a Change in
Ownership or Control of the Company. 
 (iv) Any payments or other benefits otherwise due to Executive following a Change in
Ownership or Control that could reasonably be characterized (as determined by the Company) as Contingent Compensation Payments (the “Potential 

  
 - 9 - 








 
Payments”) shall not be made until the dates provided for in this Section 4(e)(iv). Within 30 days after each date on which Executive first becomes entitled to receive (whether or not
then due) a Contingent Compensation Payment relating to such Change in Ownership or Control, the Company shall determine and notify Executive (with reasonable detail regarding the basis for its determinations) (1) which Potential Payments
constitute Contingent Compensation Payments, (2) the Eliminated Amount and (3) whether the Section 4(e)(ii) Override is applicable. Within 30 days after delivery of such notice to Executive, Executive shall deliver a response to the
Company (the “Executive Response”) stating either (A) that he agrees with the Company’s determination pursuant to the preceding sentence or (B) that he disagrees with such determination, in which case he shall set forth
(x) which Potential Payments should be characterized as Contingent Compensation Payments, (y) the Eliminated Amount, and (z) whether the Section 4(e)(ii) Override is applicable. In the event that Executive fails to deliver an
Executive Response on or before the required date, the Company’s initial determination shall be final. If Executive states in the Executive Response that he agrees with the Company’s determination, the Company shall make the Potential
Payments to Executive within three business days following delivery to the Company of the Executive Response (except for any Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on
which they are due). If Executive states in the Executive Response that he disagrees with the Company’s determination, then, for a period of 60 days following delivery of the Executive Response, Executive and the Company shall use good faith
efforts to resolve such dispute. If such dispute is not resolved within such 60-day period, such dispute shall be settled exclusively by arbitration in the greater Boston, Massachusetts area, in accordance with the rules of the American Arbitration
Association then in effect. Judgment may be entered on the arbitrator’s award in any court having jurisdiction. The Company shall, within three business days following delivery to the Company of the Executive Response, make to Executive those
Potential Payments as to which there is no dispute between the Company and Executive regarding whether they should be made (except for any such Potential Payments which are not due to be made until after such date, which Potential Payments shall be
made on the date on which they are due). The balance of the Potential Payments shall be made within three business days following the resolution of such dispute. 

(v) The Contingent Compensation Payments to be treated as Eliminated Payments shall be determined by the Company by
determining the “Contingent Compensation Payment Ratio” (as defined below) for each Contingent Compensation Payment and then reducing the Contingent Compensation Payments in order beginning with the Contingent Compensation Payment with the
highest Contingent Compensation Payment Ratio. For Contingent Compensation Payments with the same Contingent Compensation Payment Ratio, such Contingent Compensation Payment shall be reduced based on the time of payment of such Contingent
Compensation Payments with amounts having later payment dates being reduced first. For Contingent Compensation Payments with the same Contingent Compensation Payment Ratio and the same time of payment, such Contingent Compensation Payments shall be
reduced on a pro rata basis (but not below zero) prior to reducing Contingent Compensation Payments with a lower Contingent Compensation Payment Ratio. The term “Contingent Compensation Payment Ratio” shall mean a fraction the numerator of
which is the value of the applicable Contingent Compensation Payment that must be taken into account by 

  
 - 10 - 








 
Executive for purposes of Section 4999(a) of the Code, and the denominator of which is the actual amount to be received by Executive in respect of the applicable Contingent Compensation
Payment. For example, in the case of an equity grant that is treated as contingent on the Change in Ownership or Control because the time at which the payment is made or the payment vests is accelerated, the denominator shall be determined by
reference to the fair market value of the equity at the acceleration date, and not in accordance with the methodology for determining the value of accelerated payments set forth in Treasury Regulation Section 1.280G-1Q/A-24(b) or (c)). 

(vi) The provisions of this Section 4(e) are intended to apply to any and all payments or benefits available to Executive
under this Agreement or any other agreement or plan of the Company under which Executive receives Contingent Compensation Payments. 
 5.
Employee Covenants. 
 (a) Restrictive Covenant Agreement. As a condition of Executive’s employment, he will be required
to execute the Company’s Proprietary Information and Inventions Agreement (the “Restrictive Covenant Agreement”), a copy of which is attached as Exhibit C hereto. Executive agrees that if there is a conflict between any provision in
the Restrictive Covenant Agreement and any provision of this Agreement, then the provision that provides the most protection to the Company and/or its interests shall govern. 

(b) Confidential Information. Executive recognizes and acknowledges the competitive and proprietary aspects of the business of the
Company, and that as a result of Executive’s employment, Executive recognizes and acknowledges that he has had and will continue to have access to, and has been and will continue to be involved in the development of, Confidential Information
(as defined below) of the Company. As used herein, “Confidential Information” shall mean and include trade secrets, knowledge and other confidential information of the Company, which Executive has acquired, no matter from whom or on what
matter such knowledge or information may have been acquired, heretofore or hereafter, concerning the content and details of the business of the Company, and which is not known to the general public, including but not limited to: confidential and
proprietary information supplied to Executive with the legend “Confidential and Proprietary,” or equivalent, the Company’s marketing and customer support strategies, suppliers and customers, marketing and selling, business plans,
licenses, the Company’s financial information, including sales, costs, profits, prices, pricing methods, budgets and unpublished financial statements, the Company’s internal organization, employee information, information regarding the
skills and compensation of other employees of the Company and customer lists, the Company’s technology, including products, discoveries, inventions, research, experimental and development efforts, clinical studies, processes, hardware/software
design and maintenance tools, samples, media and/or molecular structures (and procedures and formulations for producing any such samples, media and/or molecular structures), formulas, methods, know-how and show-how, designs, prototypes, plans for
research and new products, and all derivatives, improvements and enhancements of any of the above and information of third parties as to which the Company has an obligation of confidentiality. 

(i) For as long as Executive is employed and at all times thereafter, Executive shall not, directly or indirectly,
communicate, disclose or divulge to any person 

  
 - 11 - 








 
or entity, or use for Executive’s own benefit or the benefit of any person (other than the Company), any Confidential Information, except as permitted in subparagraph (iii) below. Upon
termination of Executive’s employment, or at any other time at the request of the Company, Executive agrees to deliver promptly to the Company all Confidential Information, including, but not limited to, customer and supplier lists, files and
records, in Executive’s possession or under Executive’s control. Executive further agrees that he will not make or retain any copies of any of the foregoing and will so represent to the Company upon termination of Executive’s
employment. 
 (ii) Executive shall disclose immediately to the Company any trade secrets or other Confidential Information
conceived or developed by Executive at any time during Executive’s employment. Executive hereby assigns and agrees to assign to the Company Executive’s entire right, title and interest in and to all Confidential Information. Such
assignment shall include, without limitation, the rights to obtain patent or copyright protection thereon in the United States and foreign countries. Executive agrees to provide all reasonable assistance to enable the Company to prepare and
prosecute any application before any governmental agency for patent or copyright protection or any similar application with respect to any Confidential Information. Executive further agrees to execute all documents and assignments and to make all
oaths necessary to vest ownership of such intellectual property rights in the Company, as the Company may request. These obligations shall apply whether or not the subject thereof was conceived or developed at the suggestion of the Company, and
whether or not developed during regular hours of work or while on the premises of the Company. 
 (iii) Executive shall at
all times, both during and after termination of this Agreement by either Executive or the Company, maintain in confidence and shall not, without prior written consent of the Company, use, except in the course of performance of Executive’s
duties for the Company or as required by legal process (provided that Executive will promptly notify the Company of such legal process except with respect to any confidential government investigation), disclose or give to others any Confidential
Information. In the event Executive is questioned by anyone not employed by the Company or by an employee of or a consultant to the Company not authorized to receive such information, in regard to any such information or any other secret or
confidential work of the Company, or concerning any fact or circumstance relating thereto, Executive will promptly notify the Company. 

(c) Non-Competition and Non-Solicitation. Executive recognizes that the Company is engaged in a competitive business and that the
Company has a legitimate interest in protecting its trade secrets, confidential business information, and customer, business development partner, licensee, supplier, and credit and/or financial relationships. Accordingly, in exchange for valuable
consideration, including without limitation Executive’s access to confidential business information and employment, Executive agrees that, during the term hereof and for a period of twelve (12) months thereafter, Executive shall not: 

(i) directly or indirectly, whether for himself or for any other person or entity, and whether as a proprietor, principal,
shareholder, partner, agent, employee, consultant, independent contractor, or in any other capacity whatsoever, undertake or have any interest in (other than the passive ownership of publicly registered securities representing an ownership interest
of less than 1%), engage in or assume any role 

  
 - 12 - 








 
involving directly or indirectly any business activity which is directly or indirectly in competition with the products or services being developed, marketed, sold or otherwise provided by the
Company or any other business in which the Company is engaged and for which Executive has rendered services while employed by the Company, or enter into any agreement to do any of the foregoing; or 

(ii) initiate contact with (including without limitation phone calls, press releases and the sending or delivering of
announcements), or in any manner solicit, directly or indirectly, any customers, business development partners, licensors, licensees, or creditors (including institutional lenders, bonding companies and trade creditors) of the Company in an attempt
to induce or motivate them either to discontinue or modify their then prevailing or future relationship with the Company or to transfer any of their business with the Company to any person or entity other than the Company; or 

(iii) initiate contact with, or in any manner solicit, directly or indirectly, any supplier of goods, services or materials to
the Company in an attempt to induce or motivate them either to discontinue or modify their then prevailing or future relationship with the Company or to supply the same or similar inventory, goods, services or materials (except generally available
inventory, goods, services or materials) to any person or entity other than the Company; or 
 (iv) directly or indirectly
recruit, solicit or otherwise induce or influence any employee or independent contractor of the Company to discontinue or modify his or her employment or engagement with the Company, or employ or contract with any such employee or contractor for the
provision of services. 
 (d) Definition of “Customer”. The term “customer” or “customers” shall
include any person or entity (a) that is a current customer of the Company, (b) that was a customer of the Company at any time during the preceding twenty-four (24) months or (c) to which the Company made a written presentation
for the solicitation of business at any time during the preceding twenty-four (24) months. 
 (e) Reasonableness of
Restrictions. Executive further recognizes and acknowledges that (i) the types of employment which are prohibited by this Section 5 are narrow and reasonable in relation to the skills which represent Executive’s principal salable
asset both to the Company and to Executive’s other prospective employers, and (ii) the broad geographical scope of the provisions of this Section 5 is reasonable, legitimate and fair to Executive in light of the global nature of the
Company’s business, and in light of the limited restrictions on the type of employment prohibited herein compared to the types of employment for which Executive is qualified to earn Executive’s livelihood. 

(f) Remedies. Executive acknowledges that a breach of this Section 5 will cause great and irreparable injury and damage, which
cannot be reasonably or adequately compensated by money damages. Accordingly, Executive acknowledges that the remedies of injunction and specific performance shall be available in the event of such a breach, in addition to money damages, costs and
attorneys’ fees, and other legal or equitable remedies, and that the Company shall be entitled as a matter of course to an injunction pending trial, without the posting of bond or other security. Any period of restriction set forth in this
Section 5 shall be extended for a period of time equal to the duration of any breach or violation hereof. 

  
 - 13 - 








 (g) Notification. Any person employing Executive or evidencing any intention to employ
Executive may be notified as to the existence and provisions of this Agreement. 
 (h) Modification of Covenants; Enforceability. In
the event that any provision of this Section 5 is held to be in any respect an unreasonable restriction, then the court so holding may modify the terms thereof, including the period of time during which it operates or the geographic area to
which it applies, or effect any other change to the extent necessary to render this section enforceable, it being acknowledged by the parties that the representations and covenants set forth herein are of the essence of this Agreement. 

(i) Subsidiaries. For purposes of Sections 5 and 6 of this Agreement, “Company” shall include all direct and indirect
subsidiaries of the Company. An entity shall be deemed to be a subsidiary of the Company if the Company directly or indirectly owns or controls 50% or more of the equity interest in such entity. 

6. Ownership of Ideas, Copyrights and Patents. 

(a) Property of the Company. Executive agrees that all ideas, inventions, original works of authorship, developments, concepts,
know-how, improvements or trade secrets, whether patentable, copyrightable or not, which Executive may conceive, reduce to practice or develop, alone or in conjunction with another, or others, whether during or out of regular business hours, and
whether at the request or upon the suggestion of the Company, or otherwise, in the course of performing services for the Company in any capacity, whether heretofore or hereafter, (collectively, “the Inventions”) are and shall be the sole
and exclusive property of the Company, and that Executive shall not publish any of the Inventions without the prior written consent of the Company. Executive hereby assigns to the Company all of Executive’s right, title and interest in and to
all of the foregoing. Executive further represents and agrees that to the best of Executive’s knowledge and belief none of the Inventions will violate or infringe upon any right, patent, copyright, trademark or right of privacy, or constitute
libel or slander against or violate any other rights of any person, firm or corporation and that Executive will use his best efforts to prevent any such violation. 

(b) Cooperation. At any time during or after the Term, Executive agrees that he will fully cooperate with the Company, its attorneys
and agents in the preparation and filing of all papers and other documents as may be required to perfect the Company’s rights in and to any of such Inventions, including, but not limited to, executing any lawful document (including, but not
limited to, applications, assignments, oaths, declarations and affidavits) and joining in any proceeding to obtain letters patent, copyrights, trademarks or other legal rights of the United States and of any and all other countries on such
Inventions, provided that any patent or other legal right so issued to Executive, personally, shall be assigned by Executive to the Company without charge by Executive. Executive further designates the Company as his agent for, and grants to the
Company a power of attorney with full power of substitution, which power of attorney shall be deemed coupled with an interest, for the purpose of effecting the foregoing assignments from Executive to the Company. Company will bear the reasonable
expenses which it causes to be incurred in Executive’s assisting and cooperating hereunder. Executive waives all claims to moral rights in any Inventions. 

  
 - 14 - 








 7. Disclosure to Future Employers. The Company may provide in its discretion, a copy of
the covenants contained in Sections 5 and 6 of this Agreement to any business or enterprise which Executive may directly, or indirectly, own, manage, operate, finance, join, control or in which Executive participates in the ownership, management,
operation, financing, or control, or with which Executive may be connected as an officer, director, employee, partner, principal, agent, representative, consultant or otherwise. 

8. Records. Upon termination of Executive’s relationship with the Company, Executive shall deliver to the Company any property of
the Company which may be in Executive’s possession including products, materials, memoranda, notes, records, reports, or other documents or photocopies of the same. 

9. Insurance. The Company, in its sole discretion, may apply for and procure in its own name (whether or not for its own benefit)
policies of insurance insuring Executive’s life. Executive agrees to submit to reasonable medical or other examinations and to execute and deliver any applications or other instruments in writing that are reasonably necessary to effectuate such
insurance. No adverse employment actions may be based upon the results of any such exam or the failure by the Company to obtain such insurance. 

10. No Conflicting Agreements. Executive hereby represents and warrants that he has no commitments or obligations inconsistent with
this Agreement. Executive further represents that he is not bound by any employment contract, restrictive covenant or other restriction preventing him from entering into employment with, or carrying out his responsibilities for, the Company, or
which is in any way inconsistent with the terms of this Agreement. 
 11. “Market Stand-Off” Agreement. Executive agrees,
if requested by the Company and an underwriter of common stock (or other securities) of the Company, not to sell or otherwise transfer or dispose of any common stock (or other securities) of the Company held by Executive during a period not to
exceed one hundred and eighty (180) days following the effective date of an underwritten public offering of common stock of the Company, offered on a firm commitment basis pursuant to a registration statement filed with the Securities and
Exchange Commission (or any successor agency of the Federal government administrating the Securities Act of 1933, as amend, and the Securities Exchange Act of 1934, as amended) under the Securities Act of 1933, as amended, on Form S-1 or its then
equivalent, and to enter into an agreement to such effect. The Company may impose stop-transfer instructions with respect to the shares (or securities) subject to the foregoing restriction until the end of said period. 

12. General. 
 (a)
Notices. All notices, requests, consents and other communications hereunder shall be in writing, shall be addressed to the receiving party’s address as follows: 
  

			
	If to the Company:	 	Ocular Therapeutix, Inc.
		 	 36 Crosby Drive, Suite 101
 Bedford, MA
01730
 USA

Attention: Chief Executive Officer

		 	 Telephone: (781) 357-4000

		
		 	 With an email copy to: ASawhney@ocutx.com



  
 - 15 - 









			
	If to Executive:	 	 Jon Talamo, M.D.
 81 Varick Road

Newton, MA 02468
 USA

Telephone:


 or to such other address as a party may designate by notice hereunder, and shall be either (i) delivered by hand,
(ii) sent by overnight courier, or (iii) sent by registered or certified mail, return receipt requested, postage prepaid. All notices, requests, consents and other communications hereunder shall be deemed to have been given either
(i) if by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier
service, or (iii) if sent by registered or certified mail, on the fifth (5th) business day following the day such mailing is made. 

(b) Entire Agreement. This Agreement embodies the entire agreement and understanding between the parties hereto with respect to the
subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof (including without limitation, the Offer Letter that the parties had been negotiating) but does not supersede the
Restrictive Covenant Agreement. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this
Agreement. 
 (c) Modifications and Amendments. The terms and provisions of this Agreement may be modified or amended only by written
agreement executed by the parties hereto. 
 (d) Waivers and Consents. The terms and provisions of this Agreement may be waived, or
consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to
any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or
consent. 
 (e) Assignment. The Company shall assign its rights and obligations hereunder to any person or entity that succeeds to
all or substantially all of the Company’s business or that aspect of the Company’s business in which Executive is principally involved. Executive may not assign Executive’s rights and obligations under this Agreement without the prior
written consent of the Company. 
 (f) Benefit. All statements, representations, warranties, covenants and agreements in this
Agreement shall be binding on the parties hereto and shall inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this Agreement shall be construed to create any rights or obligations except among
the parties hereto, and no person or entity shall be regarded as a third-party beneficiary of this Agreement. 

  
 - 16 - 








 (g) Governing Law. This Agreement and the rights and obligations of the parties hereunder
shall be construed in accordance with and governed by the law of The Commonwealth of Massachusetts, without giving effect to the conflict of law principles thereof. 

(h) Jurisdiction and Service of Process. Any legal action or proceeding with respect to this Agreement shall be brought in the courts
of The Commonwealth of Massachusetts or of the United States of America for the District of Massachusetts. By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property, generally and
unconditionally, the jurisdiction of the aforesaid courts. Each of the parties hereto irrevocably consents to the service of process of any of the aforementioned courts in any such action or proceeding by the mailing of copies thereof by certified
mail, postage prepaid, to the party at its address set forth in Section 12(a) hereof. THE PARTIES IRREVOCABLY WAIVE ANY RIGHT TO TRIAL BY JURY AS TO ALL CLAIMS HEREUNDER. 

(i) Severability. The parties intend this Agreement to be enforced as written. However, (i) if any portion or provision of this
Agreement shall to any extent be declared illegal or unenforceable by a duly authorized court having jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it
is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law; and (ii) if any provision, or part thereof, is held
to be unenforceable because of the duration of such provision or the geographic area covered thereby, the Company and Executive agrees that the court making such determination shall have the power to reduce the duration and/or geographic area of
such provision, and/or to delete specific words and phrases (“blue-penciling”), and in its reduced or blue-penciled form such provision shall then be enforceable and shall be enforced. 

(j) Headings and Captions; Interpretation. The headings and captions of the various subdivisions of this Agreement are for convenience
of reference only and shall in no way modify, or affect the meaning or construction of any of the terms or provisions hereof. The provisions of the following Sections of this Agreement are in addition to, and do not limit, each other: Sections 6 and
5(a); Sections 7 and 5(g); Sections 12(k) and 5(f); and Sections 12(l) and 12(d). 
 (k) Injunctive Relief. Executive hereby
expressly acknowledges that any breach or threatened breach of any of the terms and/or conditions set forth in Section 5 or 6 of this Agreement will result in substantial, continuing and irreparable injury to the Company. Therefore, Executive
hereby agrees that, in addition to any other remedy that may be available to the Company, the Company shall be entitled to injunctive or other equitable relief by a court of appropriate jurisdiction. 

(l) No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy under this
Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy of the party. No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any
abandonment or discontinuance of steps to enforce any such right, 

  
 - 17 - 








 
power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a party hereto
shall not constitute a waiver of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly required under this Agreement shall entitle the party receiving such notice or demand to any other or
further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand. 

(m) Counterparts. This Agreement may be executed in one or more counterparts, and by different parties hereto on separate counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 (n) Survival.
The provisions of Sections 4, 5, 6, 7, 8, 11 and 12 shall survive the termination of this Agreement and Executive’s employment hereunder in accordance with their terms. 

IN WITNESS THEREOF, the parties hereto have executed this Agreement as of the day and year first above written. 

 

			
	Ocular Therapeutix, Inc.
	
	/s/ W. Bradford Smith
	Name:	 	W. Bradford Smith
	Title:	 	Chief Financial Officer
	
	Agreed and Accepted
	
	/s/ Jonathan Talamo
	Jon Talamo, M.D.


  
 - 18 - 








 Exhibit A 
  


	 	a.	Acting as the spokesperson for the Company with key opinion leaders at scientific conferences and advisory boards 


	 	b.	Building and maintaining relationships consistent with commercial and development objectives 


	 	c.	Ensuring that clinical development programs meet quality and safety standards required by medical and regulatory agencies 


	 	d.	Providing leadership and oversight to Medical Affairs, drug safety/pharmacovigilance, and pharmacoeconomic activities. 


	 	e.	Providing leadership and oversight to Clinical Development. 


	 	f.	Interfacing with our product development leaders to help define target product profiles and successfully translate those into the clinical development phase. 


	 	g.	Working cross-functionally to define, plan and implement all phases of clinical trials. 


	 	h.	Representing the Company with regulatory and legislative agencies, globally addressing the scientific and medical/health aspects of our product portfolio. 


	 	i.	Having P&L and budgetary responsibility for Clinical Development and Medical Affairs and providing strategic input to the annual and long-range budgetary processes. 


	 	j.	Advocating for the health and well-being of our patients. 


	 	k.	Developing processes and procedures to ensure the safety and monitoring of our products including processes to address product issues, recalls and product complaints. 


	 	l.	Providing medical input into complaint and adverse event investigations. 








 EXHIBIT B 

Sample Separation and Release Agreement General Release 

[Insert Date] 
 [Insert Executive’s address] 

Dear [Executive]: 
 In connection with the termination of your
employment with Ocular Therapeutix, Inc. (the “Company”) on [Termination Date], you are eligible to receive the Severance Compensation as described in Section 4 of the Employment Agreement executed between you and the Company
dated                     , 20     (the “Employment Agreement”) if you sign and return this letter
agreement to me by [Return Date –21 days from date of receipt of this letter agreement] and it becomes binding between you and the Company. By signing and returning this letter agreement and not revoking your acceptance, you will be
agreeing to the terms and conditions set forth in the numbered paragraphs below, including the release of claims set forth in paragraph 3. Therefore, you are advised to consult with an attorney before signing this letter agreement and you may take
up to twenty-one (21) days to do so. If you sign this letter agreement, you may change your mind and revoke your agreement during the seven (7) day period after you have signed it by notifying me in writing. If you do not so revoke, this
letter agreement will become a binding agreement between you and the Company upon the expiration of the seven (7) day period. 
 If you choose not to
sign and return this letter agreement by [Return Date-Same as Above], or if you timely revoke your acceptance in writing, you shall not receive any Severance Compensation from the Company. You will, however, receive payment for your final
wages and any unused vacation time accrued through the Termination Date, as defined below, on the Company’s regular payroll date immediately following the Termination Date. Also, regardless of signing this letter agreement, you may elect to
continue receiving group medical insurance pursuant to the federal “COBRA” law, 29 U.S.C. § 1161 et seq. If you so elect, you shall pay all premium costs on a monthly basis for as long as, and to the extent that, you
remain eligible for COBRA continuation. You should consult the COBRA materials to be provided by the Company for details regarding these benefits. All other benefits will cease upon your Termination Date in accordance with the plan documents. 

The following numbered paragraphs set forth the terms and conditions that will apply if you timely sign and return this letter agreement and do not revoke it
in writing within the seven (7) day period. 
  

	 	1.	Termination Date – Your effective date of termination from the Company is [Insert Date] (the “Termination Date”). 


 

	 	2.	 Release – In consideration of the payment of the Severance Compensation, which you acknowledge
you would not otherwise be entitled to receive, you hereby fully, forever, irrevocably and unconditionally release, remise and discharge the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of their
respective past and present officers, directors, stockholders, partners, members, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the
“Released Parties”) from any and 



  
 - 2 - 









	 	
all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings,
omissions, damages, executions, obligations, liabilities, and expenses (including attorneys’ fees and costs), of every kind and nature that you ever had or now have against any or all of the Released Parties, including, but not limited to, any
and all claims arising out of or relating to your employment with and/or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., the
Americans With Disabilities Act of 1990, 42 U.S.C. § 12101 et seq., the Age Discrimination in Employment Act, 29 U.S.C. § 621 et seq., the Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. § 2000ff
et seq., the Family and Medical Leave Act, 29 U.S.C. § 2601 et seq., the Worker Adjustment and Retraining Notification Act (“WARN”), 29 U.S.C. § 2101 et seq., the Rehabilitation Act of 1973, 29 U.S.C.
§ 701 et seq., Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. § 1681 et seq., and the Employee Retirement Income Security Act of 1974 (“ERISA”), 29 U.S.C. § 1001 et
seq., all as amended; the Massachusetts Fair Employment Practices Act, M.G.L. c.151B, § 1 et seq., the Massachusetts Civil Rights Act, M.G.L. c.12, §§ 11H and 11I, the Massachusetts Equal Rights Act, M.G.L. c.93,
§ 102 and M.G.L. c.214, § 1C, the Massachusetts Labor and Industries Act, M.G.L. c.149, § 1 et seq., the Massachusetts Privacy Act, M.G.L. c.214, § 1B and the Massachusetts Maternity Leave Act, M.G.L.
c.149, § 105(d), all as amended; all common law claims including, but not limited to, actions in defamation, intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract, including
without limitation, all claims arising from the Employment Agreement; all state and federal whistleblower claims to the maximum extent permitted by law; all claims to any non-vested ownership interest in the Company, contractual or otherwise; and
any claim or damage arising out of your employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided,
however, that nothing in this letter agreement shall (i) prevent you from filing a charge with, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission or a state fair employment practices agency
(except that you acknowledge that you may not recover any monetary benefits in connection with any such claim, charge or proceeding); (ii) deprive you of any accrued benefits to which you have acquired a vested right under any employee benefit
plan or policy, stock plan or deferred compensation arrangement, any health care continuation to the extent required by applicable law or any agreement, or any right to severance benefits or any other benefits due to you upon termination of
employment or post-employment consulting arrangements that you may have under the Employment Agreement; or (iii) deprive you of any rights you may have to be indemnified by the Company as provided in the Employment Agreement, any other
agreement between the Company and you or pursuant to the Company’s Certificate of Incorporation or by-laws. This Release shall not extend to any claims you may have against any persons that are Released Parties to the extent such claims are
(i) related solely to your ownership of the Company’s stock and (ii) unrelated to your employment with the Company. 

  

	 	3.	Non-Disclosure, Non-Competition and Non-Solicitation – You acknowledge and reaffirm your obligation to keep confidential and not disclose all non-public information concerning the Company and its
clients that you acquired during the course of your employment with the Company, as stated more fully in Section 5 of the Employment Agreement, which remains in full force and effect. 


  
 - 3 - 









	 	4.	Return of Company Property – You confirm that you have returned to the Company all keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software and
printers, wireless handheld devices, cellular phones, smartphones, tablets, etc.), Company identification, and any other Company-owned property in your possession or control and have left intact all electronic Company documents, including but not
limited to those which you developed or helped to develop during your employment. You further confirm that you have cancelled all accounts for your benefit, if any, in the Company’s name, including but not limited to, credit cards, telephone
charge cards, cellular phone and/or wireless data accounts and computer accounts. 

  

	 	5.	Business Expenses and Final Compensation – You acknowledge that you have been reimbursed by the Company for all business expenses incurred in conjunction with the performance of your employment and
that no other reimbursements are owed to you. You further acknowledge that you have received payment in full for all services rendered in conjunction with your employment by the Company, including payment for all wages, bonuses and accrued, unused
vacation time, and that no other compensation is owed to you except as provided herein. 

  

	 	6.	Non-Disparagement – To the extent permitted by law, you understand and agree that as a condition for payment to you of the Severance Compensation herein described, for a period of five years following
the date hereof you shall not make any false, disparaging or derogatory statements to any person or entity, including any media outlet, regarding the Company or any of its directors, officers, employees, agents or representatives or about the
Company’s business affairs and financial condition. Further, for a period of five years following the date hereof, neither the Company, nor any of its executive officers or members of its Board will directly or indirectly make, or cause to be
made, any false statement, observation or opinion, disparaging your reputation. 

  

	 	7.	Continued Assistance—You agree that after the Termination Date you will provide all reasonable cooperation to the Company, taking into account any duties you then owe to any future employer, including
but not limited to, assisting the Company transition your job duties, assisting the Company in defending against and/or prosecuting any litigation or threatened litigation, and performing any other tasks as reasonably requested by the Company.


  

	 	8.	 Cooperation – To the extent permitted by law, you agree to cooperate fully with the Company in
the defense or prosecution of any claims or actions which already have been brought, are currently pending, or which may be brought in the future against or on behalf of the Company, whether before a state or federal court, any state or
federal government agency, or a mediator or arbitrator. Your full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare its claims or defenses, to prepare for
trial or discovery or an administrative hearing or a mediation or arbitration and to act as a witness when 



  
 - 4 - 









	 	
requested by the Company at reasonable times designated by the Company. You agree that you will notify the Company promptly in the event that you are served with a subpoena or in the event that
you are asked to provide a third party with information concerning any actual or potential complaint or claim against the Company. 

  

	 	9.	Amendment and Waiver – This letter agreement shall be binding upon the parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly
authorized representatives of the parties hereto. This letter agreement is binding upon and shall inure to the benefit of the parties and their respective agents, assigns, heirs, executors, successors and administrators. No delay or omission by the
Company in exercising any right under this letter agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a
bar to or waiver of any right on any other occasion. 

  

	 	10.	Validity – Should any provision of this letter agreement be declared or be determined by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or
provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter agreement. 

  

	 	11.	Confidentiality – To the extent permitted by law, you understand and agree that as a condition for payment to you of the Severance Compensation herein described, the terms and contents of this letter
agreement, and the contents of the negotiations and discussions resulting in this letter agreement, shall be maintained as confidential by you and your agents and representatives and shall not be disclosed except to the extent required by federal or
state law or as otherwise agreed to in writing by the Company. 

  

	 	12.	Nature of Agreement – You understand and agree that this letter agreement is a severance agreement and does not constitute an admission of liability or wrongdoing on the part of the Company.


  

	 	13.	Acknowledgments – You acknowledge that you have been given at least twenty-one (21) days to consider this letter agreement, and that the Company advised you to consult with an attorney of your
own choosing prior to signing this letter agreement. You understand that you may revoke this letter agreement for a period of seven (7) days after you sign this letter agreement by notifying me in writing, and the letter agreement shall not be
effective or enforceable until the expiration of this seven (7) day revocation period. You understand and agree that by entering into this agreement, you are waiving any and all rights or claims you might have under the Age Discrimination in
Employment Act, as amended by the Older Workers Benefits Protection Act, and that you have received consideration beyond that to which you were previously entitled. 


 

	 	14.	Voluntary Assent – You affirm that no other promises or agreements of any kind have been made to or with you by any person or entity whatsoever to cause you to sign this letter agreement, and that you
fully understand the meaning and intent of this letter agreement. You state and represent that you have had an opportunity to fully discuss and review the terms of this letter agreement with an attorney. You further state and represent that you have
carefully read this letter agreement, understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof and sign your name of your own free act. 


  
 - 5 - 









	 	15.	Applicable Law – This letter agreement shall be interpreted and construed by the laws of the Commonwealth of Massachusetts, without regard to conflict of laws provisions. You hereby irrevocably submit
to and acknowledge and recognize the jurisdiction of the courts of the Commonwealth of Massachusetts, or if appropriate, a federal court located in the Commonwealth of Massachusetts (which courts, for purposes of this letter agreement, are the only
courts of competent jurisdiction), over any suit, action or other proceeding arising out of, under or in connection with this letter agreement or the subject matter hereof. 


 

	 	16.	Entire Agreement – This letter agreement contains and constitutes the entire understanding and agreement between the parties hereto with respect to your Severance Compensation and the settlement of
claims against the Company and cancels all previous oral and written negotiations, agreements and commitments in connection therewith. Nothing in this paragraph, however, shall modify, cancel or supersede your obligations set forth in paragraph 3
herein. 

  

	 	17.	Tax Acknowledgement – In connection with the payments and consideration provided to you pursuant to this letter agreement, the Company shall withhold and remit to the tax authorities the amounts
required under applicable law, and you shall be responsible for all applicable taxes with respect to such payments and consideration under applicable law. You acknowledge that you are not relying upon the advice or representation of the Company with
respect to the tax treatment of any of the Severance Compensation set forth in Section 4 of the Employment Agreement. 

 If you have any
questions about the matters covered in this letter agreement, please call me at [Insert Phone Number]. 
  

			
	Very truly yours,
		
	By:	 	 
		 	[Name]
		 	[Title]


 I hereby agree to the terms and conditions set forth above. I have been given at least twenty-one (21) days to
consider this letter agreement and I have chosen to execute this on the date below. I intend that this letter agreement will become a binding agreement between me and the Company if I do not revoke my acceptance in seven (7) days. 

 

					
			
	   
	 	  
	 	   

	[Executive]	 		 	Date

 To be returned to me by [Return Date – 21 days from date of receipt of this letter] 

  
 - 6 - 








 Exhibit C 

Ocular Therapeutix, Inc. 
 PROPRIETARY
INFORMATION AND INVENTIONS AGREEMENT 
 As an employee of OCULAR THERAPEUTIX, INC., its subsidiary
or its affiliate (together, the “Company”), and as a condition of my employment by the Company and in consideration of the compensation now and hereafter paid to me, I agree to the following: 

1. MAINTAINING CONFIDENTIAL INFORMATION. 

 

	 	(a)	Company Information. I agree at all times during the term of my employment and thereafter to hold in strictest confidence, and not to use, except for the benefit of the Company, or to disclose to any person, firm
or corporation, without the written authorization of the Board of Directors of the Company, any trade secrets, confidential knowledge, data or other proprietary information of the Company. By way of illustration and not limitation, such shall
include information relating to products, processes, know-how, designs, formulas, methods, samples, prototypes, developmental or experimental work, improvements, discoveries, plans for research, new products, marketing and selling, business plans,
budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers, and information regarding the skills and compensation of other employees of the Company. 


 

	 	(b)	Former Employer Information. I agree that I will not, during my employment with the Company, improperly use or disclose any proprietary information or trade secrets of my former or concurrent employers or
companies, if any, and that I will not bring onto the premises of the Company any unpublished documents or any property belonging to my former or concurrent employers or companies unless previously and specifically consented to in writing by said
employers or companies. 

  

	 	(c)	Third Party Information. I recognize that the Company has received and in the future will receive confidential or proprietary information from third parties subject to a duty on the Company’s part to
maintain the confidentiality of such information and, in some cases, to use it only for certain limited purposes. I agree that I owe the Company and such third parties, both during the term of my employment and thereafter, a duty to hold all such
confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation (except in a manner that is consistent with the Company’s agreement with the third party) or use it for the benefit of
anyone other than the Company or such third party (consistent with the Company’s agreement with the third party), unless expressly authorized to act otherwise by an officer of the Company. 


  
 - 7 - 








 2. ASSIGNMENT OF INVENTIONS AND
ORIGINAL WORKS 
  

	 	(a)	Inventions and Original Works Retained by Me. I have attached hereto as Exhibit A, a complete disclosure of all inventions, original works of authorship, developments, improvements, and trade secrets that I
have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of my employment with the Company, that I consider to be my property or the
property of third parties and that I wish to have excluded from the scope of this Agreement. If disclosure of an item on Exhibit A would cause me to violate any prior confidentiality agreement, I understand that I am not to disclose such on Exhibit
A but in the applicable space on Exhibit A I am only to disclose a cursory name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such inventions have not been made for that reason.
A space is provided on Exhibit A for such purpose. If no disclosure is attached, I represent that there are no such inventions. 

  

	 	(b)	Inventions and Original Works Assigned to the Company. I agree that I will make prompt written disclosure to the Company, will hold in trust for the sole right and benefit of the Company, and hereby assign,
without further compensation, to the Company all my right, title and interest in and to any ideas, inventions, original works of authorship, developments, improvements or trade secrets which I may solely or jointly conceive or reduce to practice, or
cause to be conceived or reduced to practice, during the period of my employment with the Company. I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment and which
are protected by copyright are “works made for hire,” as that term is defined in the United States Copyright Act (17 U.S.C., Section 101). If the copyright to any such copyrightable work shall not be the property of the Company by
operation of law, I will, without further consideration, assign to the Company all of my right, title and interest in such copyrightable work and will cooperate with the Company and its designees, at the Company’s expense, to secure, maintain
and defend for the Company’s benefit copyrights and any extensions and renewals thereof on any and all such work. To the extent I cannot transfer and assign my entire right, title, and interest to the intellectual property, or any portion
thereof, then I will assign and transfer all right, title, and interest in and to the intellectual property to the Company at the first opportunity to do so. To the extent that I cannot assign and transfer any of my full right, title, and interest
in the intellectual property, then I hereby grant the Company an irrevocable, worldwide, fully paid-up, royalty-free, exclusive license, with the right to sublicense through multiple tiers, to make, use, sell, improve, reproduce, distribute,
perform, display, transmit, manipulate in any manner, create derivative works based upon, and otherwise exploit or utilize in any manner the intellectual property. 


 

	 	(c)	 Obtaining Letters Patent, Copyright Registrations and Other Protections. I will assist the Company in
every proper way to obtain and enforce United States and foreign proprietary rights relating to any and all inventions, original works of 



  
 - 8 - 









	 	
authorship, developments, improvements or trade secrets of the Company in any and all countries. To that end I will execute, verify and deliver such documents and perform such other acts
(including appearing as a witness) the Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such proprietary rights and the assignment thereof. In addition, I will execute, verify and
deliver assignments of such proprietary rights to the Company or its designee. My obligation to assist the Company with respect to proprietary rights in any and all countries shall continue beyond the termination of my employment, but the Company
shall compensate me at a reasonable rate after my termination for the time actually spent by me at the Company’s request on such assistance. 


In the event the Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with
the actions specified in the preceding paragraph, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney-in-fact, to act for and in my behalf to execute, verify and file any such
documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if executed by me. I hereby waive and quit claim to the Company any and all claims of any nature
whatsoever which I now or may hereafter have for infringement of any proprietary rights assigned to the Company. 
  

	 	(d)	Obligation to Keep the Company Informed. In addition to my obligations under paragraph 2(b) above, during the period of my employment and for one (1) year after termination of my employment for any reason, I
will promptly disclose to the Company fully and in writing all patent applications filed by me or on my behalf. At the time of each such disclosure, I will advise the Company in writing of any inventions that I believe are not required to be
assigned to the company under Section (2b); and I will at that time provide to the Company in writing all evidence necessary to substantiate that belief. I understand that the Company will keep in confidence and will not disclose to third parties
without my consent any proprietary information disclosed in writing to the Company pursuant to this Agreement relating to inventions that are not required to be assigned to the company under the provisions of Section 2(b). I will preserve the
confidentiality of any such invention that is required to be assigned to the Company under Section 2(b). I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that may be
required by the Company) of all proprietary information developed by me and all inventions made by me during the period of my employment at the Company, which records shall be available to and remain the sole property of the Company at all times.


 3. NO CONFLICTING EMPLOYMENT; NO INDUCEMENT OF
OTHER EMPLOYEES OR SOLICITATION OF CUSTOMERS. 

I agree that during the period of my employment by the Company I will not, without the Company’s express written consent, engage in any
other employment or business activity directly related to the business in which the Company is now involved or becomes 

  
 - 9 - 








 
involved, nor will I engage in any other activities which conflict with my obligations to the Company. For a period of one (1) year after the termination or cessation of my employment with
the Company for any reason, I agree that I will not, directly or indirectly, alone or as a partner, officer, director, employee, consultant, agent, independent contractor, or stockholder of any company or business organization, engage in any
business activity which is directly or indirectly in competition with the products or services being developed, marketed, sold or otherwise provided by the Company, or which is directly or indirectly detrimental to the Company’s business
(“Competitive Activity”). I agree that, during my employment and for the one year period immediately following the cessation of my employment for any reason, I will not, and will not assist anyone else to, (a) hire or solicit for
hiring any employee of the Company or seek to persuade or induce any employee of the Company to discontinue employment with the Company, or (b) solicit, encourage or induce any independent contractor providing services to the Company to
terminate or diminish its relationship with the Company. For the purposes of this Agreement, an “employee” of the Company is any person who was such at any time within the preceding two years. I further agree that, for a period of one
(1) year after the termination or cessation of my employment with the Company, I will not in any capacity, either separately, jointly or in association with others, directly or indirectly, solicit or contact in connection with, or in
furtherance of, a Competitive Activity any of the Company’s consultants, agents, suppliers, customers or prospects that were such with respect to the Company at any time during the one year immediately preceding the date of my termination of
employment or that become such with respect to the Company at any time during the one year immediately following the date of my termination. My obligations under this Section 3 shall survive the termination or cessation of my employment. 

If any restriction set forth in this Section is found by any court of competent jurisdiction to be unenforceable because it extends for too
long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable. 

4. NO CONFLICTING OBLIGATIONS. 

I represent that my performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any
agreement or obligation of mine relating to any time prior to my employment by the Company. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict herewith. 

5. RETURN OF COMPANY DOCUMENTS. 

When I leave the employ of the Company, I will deliver to the Company (and will not keep in my possession, recreate or deliver to anyone else)
any and all devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, equipment, other documents or property, together with all copies thereof (in whatever medium recorded)
belonging to the Company, its successors or assigns whether kept at the Company, home or elsewhere. I further agree that any 

  
 - 10 - 








 
property situated on the Company’s premises and owned by the Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company
personnel at any time with or without notice. Prior to leaving, I will cooperate with the Company in completing and signing the Company’s termination statement for technical and management personnel confirming the above and my obligations under
this Agreement. 
 6. NOTIFICATION OF NEW EMPLOYER. 

In the event that I leave the employ of the Company, I hereby consent to the notification of my new employer of my rights and obligations
under this Agreement. 
 7. LEGAL AND EQUITABLE REMEDIES. 

Because my services are personal and unique and because I may have access to and become acquainted with the proprietary information of the
Company, the Company shall have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that the Company may
have for a breach of this Agreement. 
 8. GENERAL PROVISIONS. 

 

	 	(a)	Not an Employment Contract. I agree and understand that nothing in this Agreement shall confer any right with respect to continuation of my employment by the Company, nor shall it interfere in any way with my
right or the Company’s right to terminate my employment at any time, with or without cause. 

  

	 	(b)	Governing Law; Consent to Personal Jurisdiction. This Agreement will be governed by and construed according to the laws of the Commonwealth of Massachusetts, excluding conflicts of laws principles. I hereby
expressly consent to the personal jurisdiction of the state and federal courts located in Massachusetts for any lawsuit filed there against me by the Company arising from or relating to this Agreement. 


 

	 	(c)	Entire Agreement. This Agreement, and Exhibit A attached hereto and hereby incorporated herein, sets forth the final, complete and exclusive agreement and understanding between the Company and me relating to the
subject matter hereof and supersedes all prior and contemporaneous understandings and agreements relating to its subject matter. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective
unless in writing and signed by both the Company and me. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement. 


 

	 	(d)	Severability. If one or more of the provisions in this Agreement are deemed unenforceable by law, then the remaining provisions will continue in full force and effect. 


  
 - 11 - 









	 	(e)	Successors and Assigns. This Agreement will be binding upon my heirs, executors, administrators and other legal representatives and will be for the benefit of the Company, its successors and its assigns.


  

	 	(f)	Survival. The provisions of this Agreement shall survive the termination of my employment and the assignment of this Agreement by the Company to any successor in interest or other assignee. 


 

	 	(g)	Waiver. No waiver by the Company of any breach of this Agreement shall be a waiver of any preceding or succeeding breach. No waiver by the Company of any right under this Agreement shall be construed as a waiver
of any other right. The Company shall not be required to give notice to enforce strict adherence to all terms of this Agreement. 

  

	 	(h)	Notice. Any notices required or permitted hereunder shall be given to the appropriate party at the address specified below or at such other address as the party shall specify in writing. Such notice shall be
deemed given upon personal delivery, or sent by certified or registered mail, postage prepaid, three (3) days after the date of mailing. 


This Agreement shall be effective as of the first day of my employment with the Company. 

I UNDERSTAND THAT THIS AGREEMENT AFFECTS MY
RIGHTS TO INVENTIONS I MAKE DURING MY EMPLOYMENT, AND RESTRICTS MY RIGHT
TO DISCLOSE OR USE THE COMPANY’S PROPRIETARY INFORMATION DURING OR SUBSEQUENT
TO MY EMPLOYMENT. 
 I HAVE READ THIS
AGREEMENT CAREFULLY AND UNDERSTAND ITS TERMS. I HAVE COMPLETELY FILLED OUT EXHIBIT A
TO THIS AGREEMENT. 
  

							
	Dated: January 5, 2016	 		 	/s/ Jonathan M. Talamo
		 		 	SIGNATURE
			
		 		 	 
		 		 	ADDRESS


  
 - 12 - 









			
	ACCEPTED AND AGREED TO:
		
	BY:	 	/S/ W. BRADFORD SMITH
		 	BRAD SMITH
		 	CHIEF FINANCIAL OFFICER 
		
		 	OCULAR THERAPEUTIX, INC.
		 	34 CROSBY DRIVE, SUITE 105
		 	BEDFORD, MA 01730


  
 - 13 - 








 EXHIBIT A 

Ocular Therapeutix, Inc. 
 34
Crosby Drive, Suite 105 
 Bedford, MA 01730 

To whom it may concern: 
  

	 	1.	Except as listed in Section 2 below the following is a complete disclosure of all inventions or improvements relevant to the subject matter of my employment by Ocular Therapeutix, Inc. (the
“Company”) that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by the Company: 


 

			
		  	No inventions or improvements.
		
	X	  	See below. Probably not relevant but have included anyways.
	
	 
		
	 	  	Additional sheets attached.


  

	 	2.	Due to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above with respect to inventions or improvements generally listed below, the proprietary rights and duty of
confidentiality with respect to which I owe to the following party(ies): 

  

					
	Invention or Improvement	 	Party(ies)	 	Relationship

 U.S. Patents #20100208200 & #2010024483. Intraocular lens alignment using corneal center. A method for generating a
radial alignment guide for an eye that includes collecting preoperative corneal topography data. Acquired by Alcon, Inc and incorporated into the VerionTM Image Guided System. 

U.S. Patent # 8,863,749 B2; Patient Interface for ophthalmologic diagnostic and interventional procedures. Acquired by Abbott Medical Optics. 

  
 - 14 - 









	 	3.	I propose to bring to my employment the following devices, materials and documents of a former employer or other person to whom I have an obligation of confidentiality that are not generally available to the
public, which materials and documents may be used in my employment pursuant to the express written authorization of my former employer or such other person (a copy of which is attached hereto): 


 

			
	X	  	No inventions or improvements.
		
	 	  	See below
		
	 	  	Additional sheets attached.


  

									
	Date:	 	January 5, 2016	 		 	Very truly yours,
				
		 		 		 	/S/ JONATHAN TALAMO
		 		 		 	SIGNATURE


  
 - 15 -